Skip to main content

Table 2 Basic information of the patients

From: Efficacy analysis of intraoperative radiotherapy in patients with early-stage breast cancer

Items Number of cases (%)
Age (years)  
 Group 1: 40–49 15 (20.5)
 Group 2: 50–59 20 (27.4)
 Group 3: 60–69 27 (37.0)
 Group 4: ≥ 70 11 (15.1)
Diameter of tumor (cm)  
 Group 1: < 2 26 (35.6)
 Group 2: ≥ 2 47 (64.4)
Sentinel node state  
 Group 1: Negative 71 (97.3)
 Group 2: Positive 2 (2.7)
Postoperative pathological type  
 Group 1: Intraductal carcinoma 7 (9.6)
 Group 2: Infiltrating ductal carcinoma 65 (89.0)
 Group 3: Others 1 (1.4)
ER State  
 Group 1: Positive 59 (80.8)
 Group 2: Negative 14 (19.2)
PR State  
 Group 1: Positive 55 (75.3)
 Group 2: Negative 14 (19.2)
Diameter of applicator (cm)  
 Group 1: 2.5 5 (6.8)
 Group 2: 3 36 (49.3)
 Group 3: 3.5 2 (2.7)
 Group 4: 4 1 (1.4)
Irradiation dose (Gy)  
 Group 1: 16 2 (2.7)
 Group 2: 20 71 (97.3)
Histological WHO Grade  
 Group 1: Grade I–II (including grade II) 11 (15.1)
 Group 2: Above grade II 62 (85.0)
Chemotherapy regimen  
 Group 1: Not administered 20 (27.4)
 Group 2: Mainly paclitaxel 20 (27.4)
 Group 3: Mainly anthracyclines 22 (30.1)
Group 4: Others 11 (15.1)
Endocrine therapy regimen  
 Group 1: Tamoxifen 9 (12.3)
 Group 2: Anastrozole 28 (38.4)
 Group 3: Exemestane 10 (13.7)
 Group 4: Not administered 26 (35.6)
  1. ER estrogen receptor, PR progesterone receptor